S66 14.3% 16.0¢ star combo pharma limited

Ann: Termination of the Bio-E Share Sale Agreement, page-10

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 880 Posts.
    lightbulb Created with Sketch. 156
    S66 is a good business, strong cash flows, the right distribution channels and decent growth to date.

    Surprised by the lack of trading on this stock.

    I'm expecting another acquisition announcement before the end of calendar year, especially after the failed Bio-E deal. They should leverage up the company and use debt to expand.
 
watchlist Created with Sketch. Add S66 (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.